Form 4: Corcept Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, sold 10,000 shares of common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 810 Common Stock at $13.56 ($10,984) on October 1, 2026; holds 6,493 after (Direct).
- Open-market sale: disposed of 810 Common Stock at $115.40 ($93,473) on October 1, 2026; holds 5,683 after (Direct).
- Option exercise/conversion: acquired 3,357 Common Stock at $13.56 ($45,521) on October 2, 2026; holds 9,040 after (Direct).
- Option exercise/conversion: acquired 5,833 Common Stock at $19.26 ($112,344) on October 2, 2026; holds 14,873 after (Direct).
- Open-market sale: disposed of 4,446 Common Stock at $115.70 ($514,389) on October 2, 2026; holds 10,427 after (Direct).
- Open-market sale: disposed of 4,744 Common Stock at $116.54 ($552,869) on October 2, 2026; holds 5,683 after (Direct).
- Option exercise/conversion: disposed of 810 Stock option (right to buy) on October 1, 2026; holds 3,357 after (Direct).
- Option exercise/conversion: disposed of 3,357 Stock option (right to buy) on October 2, 2026 (Direct).
- Option exercise/conversion: disposed of 5,833 Stock option (right to buy) on October 2, 2026; holds 44,167 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,160,731 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Joseph Douglas Lyon — Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 810 | $14 | $11.0K | 6,493 |
| 2026-10-01 | Open-market sale | Common Stock | 810 | $115 | $93.5K | 5,683 |
| 2026-10-02 | Option exercise/conversion | Common Stock | 3,357 | $14 | $45.5K | 9,040 |
| 2026-10-02 | Option exercise/conversion | Common Stock | 5,833 | $19 | $112.3K | 14,873 |
| 2026-10-02 | Open-market sale | Common Stock | 4,446 | $116 | $514.4K | 10,427 |
| 2026-10-02 | Open-market sale | Common Stock | 4,744 | $117 | $552.9K | 5,683 |
| 2026-10-01 | Option exercise/conversion | Stock option (right to buy) | 810 | — | — | 3,357 |
| 2026-10-02 | Option exercise/conversion | Stock option (right to buy) | 3,357 | — | — | 0 |
| 2026-10-02 | Option exercise/conversion | Stock option (right to buy) | 5,833 | — | — | 44,167 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (810 shares) |
| 2026-10-01 | Open-market sale (810 shares) |
| 2026-10-02 | Option exercise/conversion (3,357 shares) |
| 2026-10-02 | Option exercise/conversion (5,833 shares) |
| 2026-10-02 | Open-market sale (4,446 shares) |
| 2026-10-02 | Open-market sale (4,744 shares) |
| 2026-10-01 | Option exercise/conversion (810 shares) |
| 2026-10-02 | Option exercise/conversion (3,357 shares) |
| 2026-10-02 | Option exercise/conversion (5,833 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, bearish, Joseph Douglas Lyon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.